Biotechnology

Dyadic International Appoints New Board Member

January 11, 2021 8:30 AM

JUPITER, FL / ACCESSWIRE / January 11, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs, and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced the appointment of Patrick Lucy, to its Board of Directors, effective...

Read more

Edesa Biotech Expands COVID-19 Clinical Study to Colombia

January 11, 2021 7:30 AM

TORONTO, ON / ACCESSWIRE / January 11, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received approval from the Ministry of Health (INVIMA) in Colombia to expand the clinical trial of its investigational drug EB05 in hospitalized COVID-19 patients. The study was previously approved in the U.S. and Canada, where enrollment is ongoing. The company reported that it has enlisted the support of a local...

Read more

Lexaria Announces Effective Date for Reverse Stock Split

January 8, 2021 4:45 PM

KELOWNA, BC / ACCESSWIRE / January 8, 2021 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it intends to effect a reverse stock split of its common stock effective as of 4:30 pm EST on January 11, 2021 (the "Reverse Split"). The Reverse Split will be conducted on a 1-for-30 basis resulting in the Company's current issued share capital of...

Read more

Viewpoint Molecular Targeting(TM) Announces Closing of Its Series A Financing with Proceeds of $13 Million

January 8, 2021 10:00 AM

Funds expected to propel two lead radiopharmaceutical programs, VMT01 and VMT-𝛼-NET into Phase 1 imaging studies beginning in 2021 and accelerate development of radioisotope production technologies CORALVILLE, IA / ACCESSWIRE / January 8, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging agents,...

Read more

MorphoSys Appoints Sung Lee as Chief Financial Officer

January 6, 2021 4:15 PM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 6, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today the appointment of Sung Lee as Chief Financial Officer, effective February 2, 2021. Mr. Lee succeeds Jens Holstein, who stepped down in December 2020, and will lead all corporate finance functions...

Read more

Molecular Partners to Present at Upcoming Healthcare Investor Conferences

January 6, 2021 11:40 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / January 6, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at or attend several upcoming virtual healthcare investor events in January, 2021. Conference Presentation Details: Event: H.C. Wainwright...

Read more

American CryoStem Enters into a Cooperative Research and Development Agreement (CRADA) to Develop Standardized Treatment Protocols

January 6, 2021 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / January 6, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a clinical stage biotechnology Company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) authorized by published code 15 U.S.C. 3710a of US Title 15 Commerce and Trade. (https://www.disa.mil/about/cto/crada-process-overview) The...

Read more

Apollo Endosurgery to Present at HC Wainwright Bioconnect Conference

January 5, 2021 4:05 PM

AUSTIN, TX / ACCESSWIRE / January 5, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures today announced that it will participate in the H.C. Wainwright Bioconnect 2021 Conference taking place virtually January 11-14, 2021. Management will provide a pre-recorded presentation which will be available to registered investors on demand via the...

Read more

Experion to Webcast Live at VirtualInvestorConference.com on January 7, 2021

January 5, 2021 8:45 AM

VANCOUVER, BC / ACCESSWIRE / January 5, 2021 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) announced today that CEO, Mr. Jarrett Malnarich will present live at VirtualInvestorConferences.com on January 7, 2021 at 3:30 PM EST / 12:30 PM PST. Experion invites shareholders, investors, advisors, and analysts to attend the real-time, interactive investor presentation. This will be a live, online...

Read more

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

January 5, 2021 8:05 AM

FRAMINGHAM, MA / ACCESSWIRE / January 5, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference taking...

Read more

PHASTAR Announces Investment by Charterhouse Capital Partners

January 5, 2021 8:00 AM

Funding will Support Expansion of Statistics and Data Science Services and Geographic Reach DURHAM, NC and LONDON, UK / ACCESSWIRE / January 5, 2021 / PHASTAR, a specialist biometrics clinical research organization (CRO) for clinical trials, announces an investment made by Charterhouse Capital Partners LLP, a long-established European private equity firm, which will support PHASTAR's growth in biometrics and geographic expansion. Charterhouse...

Read more

EV Biologics Update for 2021

January 4, 2021 9:00 AM

CHEYENNE, WY / ACCESSWIRE / January 4, 2021 / EV Biologics Corp (OTC:YECO) today announced that it has completed all its filings on OTC Markets with its 10K, 2020 filing today. The Company expects to become Pink Current within the next few weeks, then apply for a OTCQB listing. For the Company, being current allows the majority of brokers to trade in our shares, whereas before only online brokers could buy or sell the security. CEO Daniel...

Read more

MJ BIOTECH, INC., Signs Agreement with INVEST AFRICA GLOBAL LLC to provide PPE and COVID-19 Coronavirus 'Rapid Test Kits'

December 31, 2020 8:00 AM

CHEYENNE, WY / ACCESSWIRE / December 31, 2020 / MJ Biotech Inc. (OTCQB:MJTV), today announced that it has signed an agreement with Invest Africa Global LLC (IAG) to provide PPE and Covid-19 Coronavirus "Rapid Test Kits" to the Hospitals and other Medical professionals. MJTV chose this Partnership with AIG due to their vast distribution and sales network in local and international locales. IAG has developed relationship with several...

Read more

Mosaic ImmunoEngineering Inc. Announces Stock Symbol Change to “CPMV”

December 30, 2020 5:10 PM

NOVATO, CA / ACCESSWIRE / December 30, 2020 / Mosaic ImmunoEngineering Inc., (the "Company" or "Mosaic") (OTC PINK:PTSCD), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, announced today that The Financial Industry Regulatory Authority, Inc., (FINRA), has approved a change in the Company's stock symbol trading on the OTC...

Read more

Helix BioPharma Corp. Closes Private Placement

December 30, 2020 5:00 PM

RICHMOND HILL, ON / ACCESSWIRE / December 30, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced it has closed a private placement financing for gross proceeds of $3,000,000. The terms of the placement are for the purchase of units at $0.50 per unit....

Read more

Hancock Jaffe Announces Executive Promotions

December 30, 2020 4:15 PM

IRVINE, CA / ACCESSWIRE / December 30, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Hamed Alavi has been promoted to Vice President of Research and Development and Quality and that Craig Glynn has accepted the position of Chief Financial Officer. Dr. Alavi joined Hancock Jaffe in August of 2020 as the Director of Research and...

Read more

Wuhan General Group Announces $450,000 USD Private Placement by ThreeD Capital Inc.

December 30, 2020 9:00 AM

CAPE TOWN, SA / ACCESSWIRE / December 30, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update: The Company is pleased to announce a private placement financing of $450,000.00 USD with ThreeD Capital Inc. In consideration, the Company will issue 1,500,000 units...

Read more

Edesa Biotech Issues Letter to Shareholders

December 30, 2020 8:00 AM

TORONTO, ON / ACCESSWIRE / December 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, issued a letter to shareholders from its Chief Executive Officer, Par Nijhawan, providing a review of 2020. Dear Fellow Shareholders, It would be difficult to begin any year-end review without acknowledging the impact that the global health crisis has had on our communities and families, our economy, and on our...

Read more

Tetra Bio-Pharma Files New Drug Submission for REDUVO(TM) in Canada

December 30, 2020 6:30 AM

The addressable market is estimated to be $80M CDN by 2022 Tetra meets another key milestone before the end of the year OTTAWA, ON / ACCESSWIRE / December 30, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that the New Drug Submission (NDS) for the Dronabinol Soft Gel capsules, has been filed with Health Canada. If...

Read more

Meeting DEA Control Requirements - St Regis Mohawk Tribe to Develop Marijuana Grow Facility with MMJ BioPharma Cultivation and Excellis Health Solutions

December 28, 2020 2:45 PM

ST. PETERSBURG, FL / ACCESSWIRE / December 28, 2020 / MMJ Biopharma Cultivation, the premier medical cannabis cultivation and research company, today announced the signing of an agreement with Excellis Health Solutions, a global provider in end-to-end supply chain services to the life sciences industry. Excellis Health Solutions will be facilitating the movement and supply chain logistics of MMJ Biopharma Cultivation's marijuana products to...

Read more